Emergent BioSolutions to Implement Stock Repurchase Program for up to $50 Million of Its Common Stock
Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors has authorized the company’s management to implement a stock repurchase program for up to $50 million of the...
Emergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin Program
Emergent BioSolutions Inc. (NYSE:EBS) today announced a contract award by the Centers for Disease Control and Prevention (CDC) valued at $26 million over 12 months for the continued supply of...
Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika Virus
Emergent BioSolutions Inc. (NYSE:EBS) and Valneva SE (Euronext Paris:VLA) today announced the initiation of a Phase 1 clinical trial in the U.S. to evaluate the safety and immunogenicity of VLA1601,...
Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results
Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and twelve months ended December 31,...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2017 Financial Results and Conduct a Conference Call on February 22, 2018
Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 22, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve...
Emergent BioSolutions Announces Preliminary 2017 Financial Results and Provides 2018 Financial Outlook
Emergent BioSolutions Inc. (NYSE:EBS) today announced preliminary unaudited 2017 financial results and guidance for 2018. Daniel J. Abdun-Nabi, president and chief executive officer of Emergent...
Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 2 dose ranging study to evaluate the safety, pharmacokinetics, and clinical benefit of FLU-IGIV, the company’s...
Emergent BioSolutions to Participate in First Quarter 2018 Investor Conferences
Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the first quarter of...
Emergent BioSolutions Awarded Department of National Defence Contract to Supply Anthrasil to the Canadian Government
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract by the Department of National Defence (DND) valued at approximately $8 million to deliver Anthrasil®...
Emergent BioSolutions to Host 2017 Analyst & Investor Day
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company will host an analyst and investor day on December 7, 2017 in New York...
Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the manufacture of...
Emergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Senior Notes Due 2021
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has issued a Notice of Termination of Conversion Rights for all of its outstanding 2.875% Convertible Senior Notes due 2021 (“Notes”)...